Inflammatory Bowel Diseases

Skip Navigation LinksHome > July 2013 - Volume 19 - Issue 8 > Ten Years of Infliximab for Crohn’s Disease: Outcome in 469...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e318281f4c4
Original Clinical Articles

Ten Years of Infliximab for Crohn’s Disease: Outcome in 469 Patients from 2 Tertiary Referral Centers

Eshuis, Emma J. MD, PhD*,†; Peters, Charlotte P. MD*; van Bodegraven, Adriaan A. MD, PhD; Bartelsman, Joep F. MD, PhD*; Bemelman, Willem MD, PhD; Fockens, Paul MD, PhD*; D’Haens, Geert R. A. M. MD, PhD*; Stokkers, Pieter C. F. MD, PhD§; Ponsioen, Cyriel Y. MD, PhD*

Collapse Box


Background: Aim was to assess the long-term clinical efficacy of infliximab therapy in patients with Crohn’s disease treated in a cohort of 2 tertiary referral centers in the Netherlands.

Methods: All consecutive patients with Crohn’s disease treated with infliximab were assessed. Endpoints were primary clinical efficacy, sustained benefit, efficacy of retreatment, surgical intervention rates, and safety. Sustained benefit was determined by Kaplan–Meier analysis. The estimated 5-year benefit was calculated.

Results: A total of 469 patients were included. Median follow-up length was 4.5 years (interquartile range, 2.7–6.8). Seventy patients (15%) had unsuccessful remission induction, and 316 patients received maintenance therapy. Scheduled maintenance regimen was successful in 169 of 276 (61%). Episodic maintenance therapy was successful in 19 of 40 patients (48%). Estimated 5-year sustained benefit was 55.7% (95% confidence interval, 48.8–62.6). Concomitant thiopurines were associated with improved sustained benefit. A second course of infliximab after previous discontinuation was prescribed in 131 patients with similar efficacy rates. Abdominal surgical intervention rate per 100 patient-years was significantly reduced after infliximab initiation in patients with a scheduled maintenance regime (reduction, 2.70; 95% confidence interval, −4.82 to −0.35; P = 0.018). Mortality and malignancy rates were 1.9% (0.39/100 patient-years) and 3.4% (0.70/100 patient-years), respectively.

Conclusions: The present study shows an estimated 5-year sustained benefit of 55.7% in patients with Crohn’s disease treated with infliximab maintenance therapy. Remission induction and maintenance were equally successful in patients starting infliximab and patients who temporarily stopped and were retreated. Long-term use of infliximab was safe and reduced the need for surgery in patients on scheduled maintenance therapy.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.